English  |  正體中文  |  简体中文  |  Post-Print筆數 : 11 |  Items with full text/Total items : 88668/118332 (75%)
Visitors : 23511086      Online Users : 151
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    政大機構典藏 > 理學院 > 心理學系 > 期刊論文 >  Item 140.119/118861
    Please use this identifier to cite or link to this item: http://nccur.lib.nccu.edu.tw/handle/140.119/118861

    Title: Combination therapy for chronic hepatitis B: The future and beyond
    Authors: 林志陵
    Lin, Chih-Lin
    Contributors: 心理學系
    Date: 2018-08
    Issue Date: 2018-07-24 16:46:02 (UTC+8)
    Abstract: To the Editor:We read with great interest the article entitled “Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B.” by Hsu et al. in the December 2017 online edition.1 Over the past decades, antiviral therapies have dramatically improved long-term outcomes of chronic hepatitis B (CHB). For HBeAg-positive patients, early HBeAg seroconversion is an important treatment end point for a promising outcome. Through immune modulatory effect, pegylated interferon (PEG-IFN) achieved higher rates of HBeAg seroconversion than nucleos(t)ide analogues (NA). However, the response rate of PEG-IFN is unsatisfactory. Therefore, combination therapies may have potential benefits.
    Data Type: article
    DOI 連結: https://doi.org/10.1016/j.jfma.2018.04.006
    DOI: 10.1016/j.jfma.2018.04.006
    Appears in Collections:[心理學系] 期刊論文

    Files in This Item:

    File Description SizeFormat
    2018-2.pdf152KbAdobe PDF138View/Open

    All items in 政大典藏 are protected by copyright, with all rights reserved.

    社群 sharing

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback